The court also granted a summary judgment in favor of Amgen on certain Roche defenses.
该法庭同时通过了一个安进乐于接受的对于罗氏特定反诉的简要判决。
Since then, Amgen has sold more than $25 billion of Epogen, including $2.5 billion last year.
从那个时候开始，安进销售了超过250亿美元的Epogen，包括去年的25亿。
He cites in evidence a drug trial by Amgen, a biotech giant, where the researchers concluded that the drug was not effective.
Grove博士举出了这样的一个例子：那是一个由生物技术界的巨头——安进公司所进行的一项药品实验。在这项实验里，研究人员总结道，该药品并不有效。
Pfizer has been working to become the bio-technology and oncology an important one, Amgen will enable them to achieve the set target.
辉瑞一直在致力于成为生物科技和肿瘤学领域的重要一员，安进将会助其实现既定目标。
Amgen said it was pleased with the verdict and would seek an injunction to prevent Roche from releasing Mircera in the United States.
安进声称满意判决，并将寻求禁令以阻止罗氏在美国发布Mircera。
A federal judge has ruled that Mircera, a Roche anemia drug that would compete with Amgen's Epogen and Aranesp, violates an Amgen patent.
一次联邦审判认定Mircera，一个罗氏生产的用于同安进的Epogen和Aranesp竞争的药物，触犯了安进的专利权。
Amgen said it would present some new evidence, including information showing that more cancer patients are now needing blood transfusions.
安进表示将提供一些新的证据，包括如今需要输血的癌症患者正在增多等信息。
Iressa from AstraZeneca and Vectibix from Amgen are among EGFR blockers now available to treat colorectal, lung, breast and other cancers.
阿斯利康公司的Iressa和Amgen公司的Vectibix是目前用于临床治疗结直肠肿瘤、肺癌、乳腺癌和其他肿瘤的EGFR拮抗剂。
Amylin Pharmaceuticals Inc. of San Diego, which bought the rights to leptin from Amgen Inc. in 2006, is testing it, in combination with pramlintide, a diabetes drug.
圣地亚哥的Amylin PharmaceuticalsInc。于2006年从Amgen Inc。购买了瘦素的专利权，目前正在对瘦素和糖尿病药物普兰林（月太）联合作用的效果进行试验。
The video above is just the first of 15 produced by Amgen that explore various aspects of angiogenesis and potential ways to control it in beautiful, lifelike videos.
上面的图片只是安进公司制作的探索各种血管新生和如何控制这一进程的15个逼真视频中的部分截图。
Because some patents were not granted until years after Amgen applied, the patent protection could extend until 2015, longer than the 20 years contemplated by patent law.
由于一些专利在安进公司申请后好几年还没有被批准，因此这个专利保护将延长到2015年，超过了专利法规定的20年。
A jury in Federal District Court in Boston ruled that Roche's new drug, Mircera, infringed on three Amgen patents and upheld the validity of those patents and two others.
一个波士顿的联邦地区法庭陪审团判定罗氏的新药Mircera侵犯了三项安进公司专利，并且确定这些专利和其他两项专利的有效性。
The decision is a reprieve for Amgen, which is already facing declining sales of its anemia drugs because of safety concerns and a resulting cutback in reimbursement by Medicare.
这个决定缓解了安进公司，它正面临由于安全考虑而导致其贫血药物销售额的下降和随后导致的来自Medicare偿还款的减少。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
Revenues are also down, with a handful of large biotechs like Amgen (AMGN) making the lion's share of money while the majority of biotechs struggle to raise funds, especially for early stage projects.
营收也出现下滑，安进(Amgen)等少数几个大型生物技术公司掳走了大部分资金，而其他绝大多数的生物技术公司则面临着筹资困难，处于早期阶段的项目更是如此。
Revenues are also down, with a handful of large biotechs like Amgen (AMGN) making the lion's share of money while the majority of biotechs struggle to raise funds, especially for early stage projects.
营收也出现下滑，安进(Amgen)等少数几个大型生物技术公司掳走了大部分资金，而其他绝大多数的生物技术公司则面临着筹资困难，处于早期阶段的项目更是如此。
应用推荐